In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity

Cell Biology and Toxicology

Volumn 23, Issue 1, 2007, Pages 49-62

  Menna, P ^a   Minotti, G ^a   Salvatorelli, E ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Anthracyclines; Cardiotoxicity; Structure activity determinants

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; ANTHRACYCLINE; ANTIOXIDANT; ASCORBIC ACID; BMS 184476; BMS 310705; CHELATING AGENT; DAUNORUBICINOL; DOCETAXEL; DOXORUBICIN; DOXORUBICINOL; EPIRUBICIN; EPIRUBICINOL; EPOTHILONE B; IDARUBICIN; IXABEPILONE; MACROLIDE; MEN 11951; NITROXIDE DERIVATIVE; PACLITAXEL; PIPERIDINE DERIVATIVE; PROBUCOL; RAZOXANE; RETINOL; SABARUBICIN; SEMIQUINONE; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DRUG ELIMINATION; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART INJURY; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; IN VITRO STUDY; METABOLITE; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALCOHOLS; ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISACCHARIDES; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; EPIRUBICIN; HEART; HUMANS; MODELS, CARDIOVASCULAR; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS;

EID: 33845670911     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-006-0143-8     Document Type: Conference Paper

References (72)

1. Altan N, Chen Y, Schindler M, Simon SM. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med. 1998;187:1583-98.
2. Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol. 1995;13:2827-34.
3. Arcamone F, Animati F, Berettoni M, et al. Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst. 1997;89:1217-23.
4. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60:1789-92.
5. Ax W, Soldan M, Koch L, Maser E. Development of daunorubicin resistance in tumor cells by induction of carbonyl reduction. Biochem Pharmacol. 2000;59:293-300.
6. Bonadonna G, Gianni L, Santoro A, et al. Drugs ten years later: epirubicin. Ann Oncol. 1993;4:359-69.
7. Borchmann P, Hubel K, Schnell R, Engert A. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther. 1997;35:80-3.
8. Caponigro F, Willemse P, Sorio R, et al. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Invest New Drugs. 2005;23:85-9.
9. Charlier HA Jr, Olson RD, Thornock CM, et al. Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. Mol Pharmacol. 2005;67:1505-12.
10. Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, Manzini S. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J Cardiov Pharmacol. 2000;35:100-8.
11. Danesi R, Paparelli A, Bernardini N, Del Tacca M. Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue. Eur J Cancer Clin Oncol. 1988; 24:1123-31.
12. Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M. Pharmacokinetic- pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet. 2002;41:431-44.
13. D'Incalci M, Schuller J, Colombo T, Zucchetti M, Riva A. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol. 1998;25:16-20.
14. Fiedler W, Tchen N, Bloch J, et al., EORTC new drug development group. A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. Eur J Cancer. 2006;42:200-4.
15. Finlay GJ, Baguley BC. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother Pharmacol. 2000;45:417-22.
16. Forrest GL, Gonzalez B, Tseng W, Li X, Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res. 2000;60:5158-64.
17. Gambliel HA, Burke BE, Cusack BJ, et al. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem Biophys Res Commun. 2002;291:433-8.
18. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727-41.
19. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995;13:2688-99.
20. Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997;15:1906-15.
21. Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005;11:8715-21.
22. Giraud MN, Fluck M, Zuppinger C, Suter TM. Expressional reprogramming of survival pathways in rat cardiocytes by neuregulin-1beta. J Appl Physiol. 2005;99:313-22.
23. Gonzalez B, Akman S, Doroshow J, Rivera H, Kaplan WD, Forrest GL. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res. 1995;55:4646-50.
24. Gonzalez-Paz O, Polizzi D, De Cesare M, et al. Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice. Eur J Cancer. 2001;37:431-7.
25. Hasinoff BB, Schroeder PE, Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol. 2003;64:670-8.
26. Herman EH, Ferrans VJ, Myers CE, Van Vleet JF. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. 1985;45:276-81.
27. Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos. 2001;29:686-92.
28. Jeyaseelan R, Poizat C, Baker RK, et al. A novel cardiac-restricted target for doxorubicin CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J Biol Chem. 1997;272:22800-8.
29. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cel Biochem. 2002;234-235:119-24.
30. Kamath AV, Chang M, Lee FY, Zhang Y, Marathe PH. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother Pharmacol; 2005;56:145-53.
31. Kessel D. Properties of Cremophor EL micelles probed by fluorescence. Photochem Photobiol. 1992;56:447-51.
32. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM. Antioxidants and cancer therapy: a systematic review. J Clin Oncol. 2004;22:517-28.
33. Licata S, Saponiero A, Mordente A, Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol. 2000;13:414-20.
34. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol. 2002;20:1677-82.
35. Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther. 2003;74:364-71.
36. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res. 2004;10:1289-98.
37. Marcillat O, Zhang Y, Davies KJ. Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. Biochem J. 1989;259:181-9.
38. Martin M, Pienkowski T, Mackey J, et al. Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med. 2005;352:2302-13.
39. Meissner K, Sperker B, Karsten C, et al. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem. 2002;50:1351-6.
40. Minotti G, Cavaliere AF, Mordente A, et al. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest. 1995;95:1595-605.
41. Minotti G, Cairo G, Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J. 1999;13:199-212.
42. Minotti G, Giancristofaro G, Menna P, Salvatorelli E, Licata S, Gianni L. Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797. Clin Cancer Res. 2000a;6:360A.
43. Minotti G, Licata S, Saponiero A, et al. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with areduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. Chem Res Toxicol. 2000b;13:1336-41.
44. Minotti G, Saponiero A, Licata S, et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res. 2001a;7:1511-5.
45. Minotti G, Parlani M, Salvatorelli E, et al. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. Br J Pharmacol. 2001b;134:1271-8.
46. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229.
47. Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, Meucci E. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol. 2003;66:989-98.
48. Myers C, Bonow R, Palmieri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by Nacetylcysteine. Semin Oncol. 1983;10:53-5.
49. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III Trial. J Clin Oncol. 2003;21:968-75.
50. Ng SSW, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 2004;64:821-4.
51. Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 2003;63:6602-6.
52. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990;4:3076-86.
53. +-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J. 2003;370:185-93.
54. Pratesi G, De Cesare M, Caserini C, et al. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts. Clin Cancer Res. 1998;4:2833-9.
55. Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv. 1993;17:219-52.
56. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 1997;48:353-74.
57. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16:3502-8.
58. Sacco G, Giampietro R, Salvatorelli E, et al. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary alcohol metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br J Pharmacol. 2003;139:641-51.
59. Salvatorelli E, Minotti G, Vigano L, et al. BMS 247550 does not enhance doxorubicinol formation in human myocardium. Proc Am Assoc Cancer Res. 2004;45:5432A.
60. Salvatorelli E, Guarnieri S, Menna P, et al. Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem. 2006a;281:10990-1001.
61. Salvatorelli E, Menna P, Cascegna S, et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther. 2006b;318(1):424-33.
62. Schrijvers D, Bos AM, Dyck J, et al. Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the european organization for research and treatment of cancer, early clinical studies group. Ann Oncol. 2002;13:385-91.
63. Sessa C, Perotti A, Salvatorelli E, et al. Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. Eur J Cancer. 2004;40:563-70.
64. Singal PK, Iliskovic N. Adriamycin cardiomyopathy. N Engl J Med. 1998;339:900-5.
65. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem. 2000;207:77-85.
66. Spycher SE, Tabataba-Vakili S, O'Donnell VB, Palomba L, Azzi A. Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. FASEB J. 1997;11:181-8.
67. Stewart DJ, Grewaal D, Green RM, et al. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res. 1993;13:1945-52.
68. Temperini C, Messori L, Orioli P, Di Bugno C, Animati F, Giovanni U. The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes. Nucleic Acids Res. 2003;31:1464-9.
69. Toffoli G, Sorio R, Aita P, et al. Pharmacology of chronic oral daily administration of idarubicin. Haematologica. 1997;82:1-3.
70. van Vleet JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol. 1980;99:13-42.
71. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61:771-7.
72. Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem. 2003;3:151-71.